These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39153058)

  • 1. Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia.
    Dentoni M; Florean I; Farina A; Joubert B; Do LD; Honnorat J; Damato V; Fabris M; Gigli GL; Valente M; Vogrig A
    Cerebellum; 2024 Aug; ():. PubMed ID: 39153058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study.
    Farina A; Villagrán-García M; Fourier A; Pinto AL; Chorfa F; Timestit N; Alberto T; Aupy J; Benaiteau M; Birzu C; Campetella L; Cotton F; Dalle S; Delaruelle CF; Dumez P; Germi R; Le Maréchal M; Maillet D; Marignier R; Pegat A; Psimaras D; Rafiq M; Picard G; Desestret V; Quadrio I; Honnorat J; Joubert B
    Lancet Reg Health Eur; 2024 Sep; 44():101011. PubMed ID: 39170102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebellar involvement associated with immune checkpoint inhibitors: A systematic review.
    Dinoto A; Mantovani E; Ferrari S; Mariotto S; Tamburin S
    Eur J Neurol; 2023 Mar; 30(3):774-781. PubMed ID: 36325694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy.
    Sebbag E; Psimaras D; Baloglu S; Bourgmayer A; Moinard-Butot F; Barthélémy P; Tranchant C; Honnorat J; Bender L
    J Neuroimmune Pharmacol; 2022 Dec; 17(3-4):377-379. PubMed ID: 34687000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Data Brief; 2024 Apr; 53():110062. PubMed ID: 38317734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab-induced cerebellar ataxia in a patient with metastatic small cell lung cancer: A case report and literature review.
    Kapagan T; Aksu F; Yuzkan S; Bulut N; Erdem GU
    J Oncol Pharm Pract; 2024 Jan; 30(1):201-205. PubMed ID: 37321205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
    JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
    Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
    Front Oncol; 2021; 11():749064. PubMed ID: 34900695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-associated central nervous system autoimmunity.
    Valencia-Sanchez C; Sechi E; Dubey D; Flanagan EP; McKeon A; Pittock SJ; Zekeridou A
    Eur J Neurol; 2023 Aug; 30(8):2418-2429. PubMed ID: 37151179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors.
    Farina A; Villagrán-García M; Ciano-Petersen NL; Vogrig A; Muñiz-Castrillo S; Taillandier L; Michaud M; Lefilliatre M; Wang A; Lepine Z; Picard G; Wucher V; Dhairi M; Fabien N; Goncalves D; Rogemond V; Joubert B; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36446613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
    JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab.
    Zhou H; Xie X; Zhang T; Yang M; Zhou D; Yang T
    Front Immunol; 2022; 13():850540. PubMed ID: 35401563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system adverse events of immune checkpoint inhibitors.
    Farina A; Villagrán-García M; Vogrig A; Joubert B
    Curr Opin Neurol; 2024 Jun; 37(3):345-352. PubMed ID: 38483130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical presentation of immune-mediated cerebellar ataxia.
    Demarquay G; Honnorat J
    Rev Neurol (Paris); 2011 May; 167(5):408-17. PubMed ID: 21055784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.